The Senate Commerce Committee said on Wednesday it would hold a Jan. 29 hearing on President Donald Trump's nominee to lead ...
A slump in Chinese consumer confidence is holding Sanlam investments' Hannah Gooch-Peters back from buying luxury stocks like ...
NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering of 20,000,000 Class A ordinary ...
President-elect Trump has made ambitious promises to end Russia’s war in Ukraine and face down China, but he’s also contending with a growing threat of “gray zone” attacks from foreign adversaries, ...
Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...
Hosted on MSN15d
Cantor Fitzgerald: Here's why investment in China is attractiveEric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for investment in China, Johnston's stance on equities, and more. Trump signs ...
Cambridge Nutritional Sciences PLC has announced that Cantor Fitzgerald Europe has crossed the 5% threshold in its voting rights, now holding 5.207% of the total voting rights. This acquisition of ...
In a report released today, Ross Osborn from Cantor Fitzgerald initiated coverage with a Buy rating on Anteris Technologies Global Corp. (AVR – Research Report) and a price target of $9.00.
Cantor Fitzgerald analyst Ross Osborn initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $9 price target Anteris is a clinical-stage structural heart company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback